Identification
NameEthinyl Estradiol
Accession NumberDB00977  (APRD00691)
TypeSmall Molecule
GroupsApproved
Description

A semisynthetic alkylated estradiol with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally and is often used as the estrogenic component in oral contraceptives. Ethinyl estradiol is marketed mostly as a combination oral contraceptive under several brand names such as Alesse, Tri-Cyclen, Triphasil, and Yasmin. The FDA label includes a black box warning that states that combination oral contraceptives should not be used in women over 35 years old who smoke due to the increased risk of serious cardiovascular side effects.

Structure
Thumb
Synonyms
17-ethinyl-3,17-estradiol
17-ethinyl-3,17-oestradiol
17-ethinylestradiol
17alpha-Ethinyl estradiol
17α-ethynylestradiol
Ethinylestradiol
Ethinylestradiolum
Ethinyloestradiol
Ethynyl estradiol
Etinilestradiol
External IDs NSC-10973
Product Ingredients Not Available
Product Images
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Estinyl Tab 0.05mgTablet.05 mgOralSchering Plough1951-12-312000-07-11Canada
Estinyl Tab 0.5mgTablet.5 mgOralSchering Plough1951-12-312000-07-11Canada
Estinyl Tablets 0.02 Mg.Tablet.02 mgOralSchering Plough1951-12-311998-11-17Canada
JolessaKitTeva2003-10-13Not applicableUs0555 912320170913 5456 rktojs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EstinylSchering
Brand mixtures
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
AfirmelleKitAurobindo Pharma2016-11-14Not applicableUs
Alesse 21TabletOralPfizer1998-01-07Not applicableCanada
Alesse 28TabletOralPfizer1998-01-07Not applicableCanada
AltaveraKitSandoz2010-08-03Not applicableUs
Alyacen 1/35KitA S Medication Solutions2012-01-192017-06-20Us
Alyacen 7/7/7KitA S Medication Solutions2012-01-192017-06-20Us
Alysena 21TabletOralApotex Corporation2012-11-19Not applicableCanada
Alysena 28TabletOralApotex Corporation2012-11-19Not applicableCanada
AmethiaKitMayne Pharma2016-10-12Not applicableUs
AmethystTabletOralActavis Pharma Company2011-06-13Not applicableUs52544 0295 28 nlmimage10 c53a62e3
ApriKitPhysicians Total Care, Inc.2003-03-10Not applicableUs
Apri 21TabletOralTeva2008-09-29Not applicableCanada
Apri 28TabletOralTeva2008-09-29Not applicableCanada
Apri 28 DayKitTeva1999-10-22Not applicableUs00555 9043 58 nlmimage10 d5136aab
AranelleKitBarr Laboratories2004-10-04Not applicableUs00555 9066 67 nlmimage10 12368944
AubraKitAfaxys Pharma, Llc2013-10-15Not applicableUs
Aurovela 1.5/30TabletOralAurobindo Pharma2017-06-26Not applicableUs
Aurovela 1/20TabletOralAurobindo Pharma2017-06-16Not applicableUs
Aurovela 24 FeKitAurobindo Pharma2017-06-15Not applicableUs
Aurovela Fe 1/20KitAurobindo Pharma2017-06-16Not applicableUs
AvianeKitPhysicians Total Care, Inc.2005-07-08Not applicableUs00555 9045 58 nlmimage10 ab3555fa
Aviane 21TabletOralTeva2007-11-05Not applicableCanada
Aviane 28TabletOralTeva2007-11-05Not applicableCanada
Aviane 28 DayKitRebel Distributors1995-08-24Not applicableUs
AyunaKitAurobindo Pharma2016-09-23Not applicableUs
BalzivaKitTeva2006-10-16Not applicableUs00555 9034 58 nlmimage10 d9136ceb
Blisovi 24 FeKitLupin Pharmaceuticals2015-11-25Not applicableUs
Blisovi Fe 1.5/30KitLupin Pharmaceuticals2016-01-05Not applicableUs
Blisovi Fe 1/20KitLupin Pharmaceuticals2015-12-08Not applicableUs
BreviconKitActavis Pharma Company1976-03-29Not applicableUs
Brevicon 0.5/35 21 TabTabletOralSyntex Inc.1976-12-311996-09-30Canada
Brevicon 0.5/35 28 TabTabletOralSyntex Inc.1976-12-311996-09-30Canada
Brevicon 0.5/35 Tablets (21-day Pack)TabletOralPfizer1976-12-31Not applicableCanada
Brevicon 0.5/35 Tablets (28-day Pack)TabletOralPfizer1996-08-14Not applicableCanada
Brevicon 1/35 21 TabTabletOralSyntex Inc.1982-12-311996-09-30Canada
Brevicon 1/35 28 TabTabletOralSyntex Inc.1982-12-311996-09-30Canada
Brevicon 1/35 Tablets (21-day Pack)TabletOralPfizer1996-08-14Not applicableCanada
Brevicon 1/35 Tablets (28-day Pack)TabletOralPfizer1996-09-16Not applicableCanada
BriellynKitGlenmark Pharmaceuticals Inc.,Usa2011-03-23Not applicableUs
CamreseKitTeva2010-07-28Not applicableUs00093 3134 82 nlmimage10 39369c94
camrese LoKitTeva2010-12-07Not applicableUs00093 6148 82 nlmimage10 7f36bfd5
CaziantKitWatson Pharma, Inc.2005-05-012017-07-22Us52544 0959 28 nlmimage10 c53ae297
Caziant Triphasic RegimenKitMayne Pharma2016-08-03Not applicableUs
Centrisa 21TabletOralPatriot A Division Of Janssen IncNot applicableNot applicableCanada
Centrisa 28TabletOralPatriot A Division Of Janssen IncNot applicableNot applicableCanada
Centrisa Lo 21TabletOralPatriot A Division Of Janssen IncNot applicableNot applicableCanada
Centrisa Lo 28TabletOralPatriot A Division Of Janssen IncNot applicableNot applicableCanada
ChatealKitAfaxys Pharma, Llc2013-01-22Not applicableUs
Cléo -35TabletOralAltius Healthcare Inc2015-10-30Not applicableCanada
CryselleKitPhysicians Total Care, Inc.2003-10-16Not applicableUs
Cyclafem 1/35KitQualitest2010-11-12Not applicableUs
Cyclafem 7/7/7KitQualitest2010-11-16Not applicableUs
Cyclen Tablets (21 Day)TabletOralJanssen Pharmaceuticals1992-12-31Not applicableCanada
Cyclen Tablets (28 Day)TabletOralJanssen Pharmaceuticals1992-12-31Not applicableCanada
CyclessaKitOrganon2000-12-20Not applicableUs
Cyestra-35TabletOralPaladin Labs Inc2007-04-03Not applicableCanada
CyonanzKitAurobindo Pharma2016-10-21Not applicableUs
CyredKitAfaxys Pharma, Llc2015-08-07Not applicableUs
Dasetta 1/35KitOralNorth Star Rx Llc2012-06-01Not applicableUs
Dasetta 7/7/7KitOralNorth Star Rx Llc2012-06-01Not applicableUs
DayseeKitLupin Pharmaceuticals2013-04-10Not applicableUs
DelylaKitOhm Laboratories, Inc.2014-05-26Not applicableUs
Demulen 30 (21 Day Pack)TabletOralPfizer1979-12-31Not applicableCanada
Demulen 30 (28 Day Pack)TabletOralPfizer1979-12-31Not applicableCanada
Demulen 50 (21 Day Pack)TabletOralPfizer1970-12-312005-04-01Canada
Demulen 50 (28 Day Pack)TabletOralPfizer1970-12-312005-04-01Canada
DesogenKitOrganon2010-06-10Not applicableUs
Desogestrel and Ethinyl EstradiolKitNorth Star Rx Llc2014-05-30Not applicableUs
Diane-35TabletOralBayer1998-04-08Not applicableCanada
Drospirenone and Ethinyl EstradiolKitMylan Pharmaceuticals2015-08-28Not applicableUs
Drospirenone and Ethinyl Estradiol Tablets 21TabletOralJai Pharma LimitedNot applicableNot applicableCanada
Drospirenone and Ethinyl Estradiol Tablets 28TabletOralJai Pharma LimitedNot applicableNot applicableCanada
Drospirenone and Ethinyl Estradiol Tablets USP (21-day Regimen)TabletOralGlenmark Pharmaceuticals, IncNot applicableNot applicableCanada
Drospirenone and Ethinyl Estradiol Tablets USP (28-day Regimen)TabletOralGlenmark Pharmaceuticals, IncNot applicableNot applicableCanada
ElinestKitOralNorth Star Rx Llc2012-07-01Not applicableUs
EmoquetteKitPar Pharmaceutical2011-02-25Not applicableUs
EnpresseKitRebel Distributors2010-12-20Not applicableUs00555 9047 58 nlmimage10 8c36c666
EnskyceKitLupin Pharmaceuticals2013-05-07Not applicableUs
Esme 21TabletOralMylan Pharmaceuticals2012-07-05Not applicableCanada
Esme 28TabletOralMylan Pharmaceuticals2012-07-05Not applicableCanada
EstaryllaKitSandoz2013-02-01Not applicableUs
Ethynodiol Diacetate and Ethinyl EstradiolKitMylan Pharmaceuticals2016-11-30Not applicableUs
Evra -(6/0.60)Patch, extended releaseTransdermalJanssen Pharmaceuticals2003-12-24Not applicableCanada
Evra -(6/0.75)Patch, extended releaseTransdermalJanssen Pharmaceuticals2002-10-242006-02-22Canada
FalessaKitAvion Pharmaceuticals, Llc2014-02-17Not applicableUs
FalminaKitOralNorth Star Rx Llc2012-07-01Not applicableUs
FEMCON FeKitWarner Chilcott2006-11-01Not applicableUs
FemhrtTabletOralPhysicians Total Care, Inc.2002-09-24Not applicableUs
FemynorKitAmneal Pharmaceuticals2016-06-15Not applicableUs
Freya 21TabletOralMylan Pharmaceuticals2012-11-22Not applicableCanada
Freya 28TabletOralMylan Pharmaceuticals2012-11-22Not applicableCanada
FyavolvTablet, film coatedOralLupin Pharmaceuticals2016-02-05Not applicableUs
GeneressTablet, chewableOralActavis Specialty Pharmaceuticals CoNot applicableNot applicableCanada
GianviKitPhysicians Total Care, Inc.2010-10-21Not applicableUs
GildagiaKitPar Pharmaceutical2012-12-23Not applicableUs
Gildess 1.5/30Tablet, film coatedOralQualitest2012-07-24Not applicableUs
Gildess 1/20Tablet, film coatedOralQualitest2012-07-24Not applicableUs
IndayoTabletOralMylan Pharmaceuticals2016-09-01Not applicableCanada
IntrovaleKitSandoz2010-09-27Not applicableUs
IsibloomKitSandoz2017-01-20Not applicableUs
Jevantique LoTabletOralActavis Pharma Company2015-11-09Not applicableUs
JinteliTabletOralPhysicians Total Care, Inc.2011-04-26Not applicableUs
JolessaKitPhysicians Total Care, Inc.2009-06-24Not applicableUs00555 9123 66 nlmimage10 6636b375
JuleberKitNorth Star Rx Llc2013-07-12Not applicableUs
Junel 1.5/30TabletOralBarr Laboratories2003-09-18Not applicableUs00555 9027 42 nlmimage10 f72f7bdb
Junel 1/20TabletOralBarr Laboratories2003-09-18Not applicableUs00555 9025 42 nlmimage10 f22f796b
Junel Fe 1.5/30KitBarr Laboratories2003-09-18Not applicableUs
Junel Fe 1/20KitBarr Laboratories2003-09-18Not applicableUs00555 9026 58 nlmimage10 202f901c
Junel Fe 24KitTeva2015-05-29Not applicableUs00093 5328 62 nlmimage10 f642fb77
Kaitlib FeKitLupin Pharmaceuticals2015-12-17Not applicableUs
KalligaKitAurobindo Pharma2017-05-17Not applicableUs
Kelnor 1/35KitPhysicians Total Care, Inc.2008-09-16Not applicableUs00555 9064 58 nlmimage10 0e368734
KimidessKitPar Pharmaceutical2015-06-08Not applicableUs
KurveloKitLupin Pharmaceuticals2012-10-26Not applicableUs
LarissiaKitAmneal Pharmaceuticals2016-02-29Not applicableUs
LeenaKitOralActavis Pharma Company2005-01-12Not applicableUs
LessinaKitTeva2002-04-22Not applicableUs00555 9014 67 nlmimage10 9b2fcdce
LevonestKitOralNorth Star Rx Llc2012-06-01Not applicableUs
Levonorgestrel and Ethinyl EstradiolKitMylan Pharmaceuticals2015-04-27Not applicableUs
Levonorgestrel and Ethinyl Estradiol and Ethinyl EstradiolKitLupin Pharmaceuticals2011-12-02Not applicableUs
Levonorgestrel and Ethinyl Estradiol Tablets, 0.1 Mg/0.02 mgTabletOralLupin PharmaceuticalsNot applicableNot applicableCanada
LevoraKitRebel Distributors2002-04-10Not applicableUs52544 0279 28 nlmimage10 fb447d83
LillowKitAmneal Pharmaceuticals2016-07-03Not applicableUs
Linessa 21TabletOralAspen Pharma Trading Limited2006-06-13Not applicableCanada
Linessa 28TabletOralAspen Pharma Trading Limited2006-06-13Not applicableCanada
Lo Loestrin FeKitA S Medication Solutions2010-12-012017-06-20Us
Lo Minastrin FeKitAllergan2013-08-12Not applicableUs
Lo SimpesseKitAurobindo Pharma2017-04-28Not applicableUs
Lo-femenal 21 TabletsTabletOralPfizer2001-05-142014-04-04Canada
Lo/Ovral-28KitA S Medication Solutions1976-03-012017-06-20Us
Loestrin 1.5/30TabletOralWarner Chilcott1974-12-31Not applicableCanada
Loestrin 1.5/30 21 DayTabletOralTeva Women's Health2008-10-012015-11-30Us51285 0082 97 nlmimage10 e92f74eb
Loestrin 1/20 21 DayTabletOralTeva Women's Health2008-10-012015-11-30Us51285 0079 97 nlmimage10 ee2f775b
Loestrin 21 1.5/30 21 DayTabletOralTeva Women's Health2014-06-30Not applicableUs51285 0127 97 nlmimage10 8f42c7e6
Loestrin 21 1/20 21 DayTabletOralTeva Women's Health2014-06-30Not applicableUs51285 0131 97 nlmimage10 8a42c576
Loestrin 24 FeKitPhysicians Total Care, Inc.2010-01-28Not applicableUs
LoloTabletOralAllergan Pharma Co.2014-03-24Not applicableCanada
Lomedia 24 FeKitOralAmneal Pharmaceuticals of New York Llc2013-12-20Not applicableUs
LorynaKitSandoz2011-03-28Not applicableUs
Low-OgestrelKitOralPhysicians Total Care, Inc.2009-09-24Not applicableUs
LuteraKitWatson Pharma, Inc.2004-11-18Not applicableUs
Lutera 21TabletOralCobalt Laboratories2013-06-18Not applicableCanada
Lutera 28TabletOralCobalt Laboratories2013-06-18Not applicableCanada
Marfem 21TabletOralNovopharm LimitedNot applicableNot applicableCanada
Marfem 28TabletOralNovopharm LimitedNot applicableNot applicableCanada
MarlissaKitPreferreed Pharmaceuticals Inc.2016-10-17Not applicableUs
Marvelon 21TabletOralMerck Ltd.1993-12-31Not applicableCanada
Marvelon 28TabletOralMerck Ltd.1993-12-31Not applicableCanada
MicrogestinTabletOralActavis Pharma Company2014-08-18Not applicableUs
Microgestin 1.5/30TabletOralMayne Pharma2016-08-05Not applicableUs
Microgestin 1/20TabletOralMayne Pharma2016-08-05Not applicableUs
MiliKitAurobindo Pharma2016-07-07Not applicableUs
Min-ovral 21TabletOralPfizer1995-12-31Not applicableCanada
Min-ovral 21 TabTabletOralWyeth Ltd.1989-12-311996-09-10Canada
Min-ovral 28TabletOralPfizer1995-12-31Not applicableCanada
Min-ovral 28 TabTabletOralWyeth Ltd.1989-12-311996-09-10Canada
Minastrin 24 FeKitWarner Chilcott2013-06-14Not applicableUs
Minestrin 1/20TabletOralWarner Chilcott1975-12-31Not applicableCanada
Mirvala 21TabletOralApotex Corporation2014-01-07Not applicableCanada
Mirvala 28TabletOralApotex Corporation2014-01-07Not applicableCanada
ModiconKitJanssen Pharmaceuticals1984-04-042017-04-14Us
Mono-LinyahKitNorth Star Rx Llc2012-05-23Not applicableUs
MonoNessaKitProficient Rx LP2003-01-01Not applicableUs
MyaTabletOralApotex Corporation2014-05-20Not applicableCanada
MyzilraKitCentral Texas Community Health Centers2012-01-12Not applicableUs
NeconKitRebel Distributors1987-01-29Not applicableUs
Necon (28 Day Regimen)KitMayne Pharma2016-07-18Not applicableUs
Necon 1/35KitWatson Pharma, Inc.1987-01-29Not applicableUs
Necon 1/35 (28 Day Regimen)KitTeva2016-12-01Not applicableUs
Necon 777KitWatson Pharma, Inc.2002-12-07Not applicableUs52544 0936 28 nlmimage10 02450128
Necon 777 777KitDispensing Solutions, Inc.2002-12-07Not applicableUs
Nexesta FeKitAurobindo Pharma2017-02-02Not applicableUs
NikkiKitLupin Pharmaceuticals2014-07-30Not applicableUs
Norethindrone Acetate and Ethinyl EstradiolTabletOralMylan Pharmaceuticals2014-07-11Not applicableUs
Norethindrone Acetate and Ethinyl Estradiol and Ferrous FumarateKitWarner Chilcott2016-05-01Not applicableUs
Norethindrone and Ethinyl Estradiol and Ferrous FumarateKitLupin Pharmaceuticals2011-10-04Not applicableUs
Norgestimate and Ethinyl EstradiolKitMylan Pharmaceuticals2015-12-31Not applicableUs
NorinylKitActavis Pharma Company1974-12-27Not applicableUs
Nortrel 21 DayTabletOralTeva2001-06-13Not applicableUs00555 9009 42 nlmimage10 e52f72db
Nortrel 28 DayKitTeva2001-06-06Not applicableUs00555 9008 67 nlmimage10 252f928c
Nortrel 7/7/7 (28 Day Regimen)KitPhysicians Total Care, Inc.2008-08-19Not applicableUs00555 9012 58 nlmimage10 762fbb3d
Novo-cyproterone/ethinyl EstradiolTabletOralTeva2008-09-26Not applicableCanada
NuvaRingInsert, extended releaseVaginalPhysicians Total Care, Inc.2011-11-04Not applicableUs
Nylia 1/35KitAurobindo Pharma2016-10-21Not applicableUs
Nylia 7/7/7KitAurobindo Pharma2016-10-21Not applicableUs
OcellaKitPhysicians Total Care, Inc.2008-07-31Not applicableUs00555 9131 67 nlmimage10 233611d0
OgestrelKitActavis Pharma Company1999-12-15Not applicableUs52544 0848 28 nlmimage10 18498c6c
OrsythiaKitOralA S Medication Solutions2011-05-112017-06-20Us
Ortho 0.5/35 Tablets (21 Day)TabletOralJanssen Pharmaceuticals1974-12-31Not applicableCanada
Ortho 0.5/35 Tablets (28 Day)TabletOralJanssen Pharmaceuticals1974-12-31Not applicableCanada
Ortho 1/35 Tablets (21 Day)TabletOralJanssen Pharmaceuticals1980-12-31Not applicableCanada
Ortho 1/35 Tablets (28 Day)TabletOralJanssen Pharmaceuticals1980-12-31Not applicableCanada
Ortho 10/11 Tablets (21 Day)TabletOralJanssen Pharmaceuticals1981-12-312002-07-31Canada
Ortho 10/11 Tablets (28 Day)TabletOralJanssen Pharmaceuticals1981-12-312002-07-31Canada
Ortho 7/7/7 Tablets (21 Day)TabletOralJanssen Pharmaceuticals1983-12-31Not applicableCanada
Ortho 7/7/7 Tablets (28 Day)TabletOralJanssen Pharmaceuticals1983-12-31Not applicableCanada
Ortho CeptKitJanssen Pharmaceuticals1992-12-14Not applicableUs
Ortho CyclenKitJanssen Pharmaceuticals1989-12-29Not applicableUs50458 0197 00 nlmimage10 c54562ab
Ortho EvraPatch, extended releaseTransdermalJanssen Pharmaceuticals2001-11-20Not applicableUs
Ortho Novum 135KitJanssen Pharmaceuticals1977-06-23Not applicableUs
Ortho Tri CyclenKitPhysicians Total Care, Inc.2005-05-13Not applicableUs
ORTHO TRI CYCLEN LoKitPhysicians Total Care, Inc.2003-01-23Not applicableUs
Ortho-cept Tablets (21 Day)TabletOralJanssen Pharmaceuticals1993-12-312007-08-11Canada
Ortho-cept Tablets (28 Day)TabletOralJanssen Pharmaceuticals1993-12-312015-04-22Canada
Ortho-Novum 777KitA S Medication Solutions1984-04-042017-06-20Us
Ovcon 35KitWarner Chilcott2005-06-01Not applicableUs
Ovima 21TabletOralApotex Corporation2013-08-27Not applicableCanada
Ovima 28TabletOralApotex Corporation2013-08-27Not applicableCanada
Ovral 21TabletOralPfizer1996-09-202010-09-30Canada
Ovral 21 TabTabletOralWyeth Ltd.1968-12-311997-08-14Canada
Ovral 28 TabletsTabletOralWyeth Ltd.1995-12-312006-08-04Canada
Ovral 28tabTabletOralWyeth Ltd.1970-12-311996-09-10Canada
Pirmella 1/35KitLupin Pharmaceuticals2013-06-21Not applicableUs
Pirmella 7/7/7KitLupin Pharmaceuticals2013-05-15Not applicableUs
PortiaKitTeva2002-06-27Not applicableUs00555 9020 58 nlmimage10 4b36a5f5
Portia 21TabletOralTeva2007-08-14Not applicableCanada
Portia 28TabletOralTeva2007-08-14Not applicableCanada
Preven Emergency ContraceptiveTabletOralGynÉtics Ltd/LtÉeNot applicableNot applicableCanada
Preven TabletsTabletOralShire Pharma Canada Ulc1999-09-162001-08-02Canada
PrevifemKitQualitest2004-01-09Not applicableUs00603 7642 01 nlmimage10 17418bcc
Previfem (21day)TabletOralNovopharm LimitedNot applicableNot applicableCanada
Previfem (28day)TabletOralNovopharm LimitedNot applicableNot applicableCanada
Qismette 21TabletOralLupin PharmaceuticalsNot applicableNot applicableCanada
Qismette 28TabletOralLupin PharmaceuticalsNot applicableNot applicableCanada
QuasenseKitOralWatson Pharma, Inc.2006-09-06Not applicableUs
RajaniKitActavis Pharma Company2016-10-12Not applicableUs
Ran-cyproterone/ethinyl EstradiolTabletOralRanbaxy Inc.2015-03-26Not applicableCanada
ReclipsenKitActavis Pharma Company2005-08-01Not applicableUs
Reclipsen 21TabletOralActavis Pharma Company2014-06-29Not applicableCanada
Reclipsen 28TabletOralActavis Pharma Company2014-06-29Not applicableCanada
Reclipsen 28 DayKitTeva2017-01-01Not applicableUs
Sarensis 21TabletOralPatriot A Division Of Janssen IncNot applicableNot applicableCanada
Sarensis 28TabletOralPatriot A Division Of Janssen IncNot applicableNot applicableCanada
SeasonaleTabletOralTeva Women's Health2008-01-03Not applicableCanada
SeasoniqueTabletOralTeva Women's Health2011-04-18Not applicableCanada
Select 1/35 (21-day)TabletOralPfizer1997-05-08Not applicableCanada
Select 1/35 (28-day)TabletOralPfizer1997-05-08Not applicableCanada
SetlakinKitNorth Star Rx Llc2015-08-01Not applicableUs
SimliyaKitAurobindo Pharma2017-03-22Not applicableUs
SimpesseKitAurobindo Pharma2017-04-07Not applicableUs
SprintecKitRebel Distributors2010-11-22Not applicableUs00555 9016 58 nlmimage10 492fa48d
SronyxKitWatson Pharma, Inc.2006-05-31Not applicableUs
SyedaKitSandoz2011-03-28Not applicableUs
Synphasic 21 TabletsTabletOralPfizer1996-08-14Not applicableCanada
Synphasic 28 TabletsTabletOralPfizer1996-08-14Not applicableCanada
Synphasic-28 TabletsTabletOralSyntex Inc.1986-12-311996-09-30Canada
TARINA Fe 1/20KitAfaxys Inc.2014-09-15Not applicableUs
TaytullaKitAllergan2016-05-01Not applicableUs
Tilia FeKitRebel Distributors2010-12-01Not applicableUs
Tri FemynorKitAmneal Pharmaceuticals2016-10-28Not applicableUs
Tri-cyclen Lo (-21 Day)TabletOralJanssen Pharmaceuticals2005-01-27Not applicableCanada
Tri-cyclen Lo (28 Day)TabletOralJanssen Pharmaceuticals2005-01-27Not applicableCanada
Tri-cyclen Tablets - 21-dayTabletOralJanssen Pharmaceuticals1993-12-31Not applicableCanada
Tri-cyclen Tablets - 28-dayTabletOralJanssen Pharmaceuticals1993-12-31Not applicableCanada
Tri-EstaryllaKitSandoz2013-02-01Not applicableUs
Tri-Legest Fe 28 DayKitTeva2007-10-26Not applicableUs00555 9032 70 nlmimage10 5f2fafcd
Tri-lena 21TabletOralActavis Pharma CompanyNot applicableNot applicableCanada
Tri-lena 28TabletOralActavis Pharma CompanyNot applicableNot applicableCanada
Tri-lena Lo 21TabletOralActavis Pharma CompanyNot applicableNot applicableCanada
Tri-lena Lo 28TabletOralActavis Pharma CompanyNot applicableNot applicableCanada
Tri-LinyahKitNorth Star Rx Llc2012-05-30Not applicableUs
Tri-Lo- EstaryllaKitSandoz2015-11-25Not applicableUs
Tri-LO-marziaKitLupin Pharmaceuticals2012-08-22Not applicableUs
Tri-Lo-MiliKitAurobindo Pharma2016-11-04Not applicableUs
Tri-Lo-SprintecKitTeva2015-12-30Not applicableUs00093 2140 62 nlmimage10 8f4a4782
Tri-MiliKitAurobindo Pharma2016-07-06Not applicableUs
Tri-NorinylKitOralActavis Pharma Company1984-04-13Not applicableUs
Tri-PrevifemKitQualitest2004-03-26Not applicableUs
Tri-previfem (21 Day)TabletOralNovopharm LimitedNot applicableNot applicableCanada
Tri-previfem (28 Day)TabletOralNovopharm LimitedNot applicableNot applicableCanada
Tri-SprintecKitRebel Distributors2011-01-25Not applicableUs
Tricira LoTabletOralApotex Corporation2014-06-09Not applicableCanada
TriNessaKitRebel Distributors2007-08-17Not applicableUs
TriNessa LoKitActavis Pharma Company2015-12-31Not applicableUs
Triphasil 21TabletOralWyeth Ltd.1995-12-312007-10-23Canada
Triphasil 21 TabTabletOralWyeth Ltd.1989-12-311996-09-10Canada
Triphasil 28TabletOralWyeth Ltd.1995-12-312007-10-25Canada
Triphasil 28 TabTabletOralWyeth Ltd.1989-12-311996-09-10Canada
Triquilar 21TabletOralBayer1987-12-31Not applicableCanada
Triquilar 28TabletOralBayer1987-12-31Not applicableCanada
TrivoraKitMayne Pharma2016-08-03Not applicableUs
Velivet Triphasic RegimenKitPhysicians Total Care, Inc.2004-03-26Not applicableUs00555 9051 67 nlmimage10 5936ace5
VesturaKitOralActavis Pharma Company2012-01-19Not applicableUs
Vienva TMKitSandoz2015-11-05Not applicableUs
VyfemlaKitLupin Pharmaceuticals2013-12-23Not applicableUs
WeraKitOralNorth Star Rx Llc2012-06-01Not applicableUs
Wymzya FeKitLupin Pharmaceuticals2012-12-19Not applicableUs
XulanePatchTransdermalMylan Pharmaceuticals2014-04-16Not applicableUs
YasminKitPhysicians Total Care, Inc.2002-01-15Not applicableUs
Yasmin 21TabletOralBayer2004-12-22Not applicableCanada
Yasmin 28TabletOralBayer2004-12-22Not applicableCanada
Yasmin PlusTabletOralBayerNot applicableNot applicableCanada
YazKitPhysicians Total Care, Inc.2007-11-02Not applicableUs
Yaz PlusTabletOralBayer2013-03-01Not applicableCanada
Zamine 21TabletOralApotex Corporation2014-01-30Not applicableCanada
Zamine 28TabletOralApotex Corporation2014-01-30Not applicableCanada
ZarahKitOralWatson Pharma, Inc.2010-09-07Not applicableUs
Zarah 21TabletOralCobalt Laboratories2013-06-04Not applicableCanada
Zarah 28TabletOralCobalt Laboratories2013-06-04Not applicableCanada
ZenchentKitWatson Pharma, Inc.2007-01-012017-03-01Us
Zenchent 0.4/35KitTeva2017-01-01Not applicableUs
Zenchent FEKitWatson Pharma, Inc.2011-09-262017-01-31Us
ZeosaKitTeva2011-03-252016-02-04Us
Zovia 1/35KitMayne Pharma2016-07-18Not applicableUs
Zovia 1/35E-28KitOralPhysicians Total Care, Inc.2003-06-23Not applicableUs
Zovia 1/50E-28KitOralPhysicians Total Care, Inc.2003-04-21Not applicableUs
Categories
UNII423D2T571U
CAS number57-63-6
WeightAverage: 296.4034
Monoisotopic: 296.177630012
Chemical FormulaC20H24O2
InChI KeyBFPYWIDHMRZLRN-SLHNCBLASA-N
InChI
InChI=1S/C20H24O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3/t16-,17-,18+,19+,20+/m1/s1
IUPAC Name
(1S,10R,11S,14R,15S)-14-ethynyl-15-methyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-2(7),3,5-triene-5,14-diol
SMILES
[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
Pharmacology
Indication

For treatment of moderate to severe vasomotor symptoms associated with the menopause, female hypogonadism, prostatic carcinoma-palliative therapy of advanced disease, breast cancer, as an oral contraceptive, and as emergency contraceptive.

Structured Indications
Pharmacodynamics

Ethinyl estradiol is a synthetic derivative of the natural estrogen estradiol. It is one of two estrogens currently used in oral contraceptive pills. The other, mestranol, is converted to ethinyl estradiol before it is biologically active. Ethinyl estradiol and norethindrone are used together as an oral contraceptive agent.

Mechanism of action

Estrogens diffuse into their target cells and interact with a protein receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. This cascade is initiated by initially binding to the estrogen receptors. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (GnRH).

TargetKindPharmacological actionActionsOrganismUniProt ID
Estrogen receptor alphaProteinyes
agonist
HumanP03372 details
Nuclear receptor subfamily 1 group I member 2Proteinunknown
agonist
HumanO75469 details
Sex hormone-binding globulinProteinunknownNot AvailableHumanP04278 details
Related Articles
Absorption

Rapid and complete absorption follows oral intake of ethinyl estradiol (bioavailability 43%).

Volume of distributionNot Available
Protein binding

97%

Metabolism

Hepatic. Quantitatively, the major metabolic pathway for ethinyl estradiol, both in rats and in humans, is aromatic hydroxylation, as it is for the natural estrogens.

SubstrateEnzymesProduct
Ethinyl Estradiol
2β-OH-17β-ethinylestradiolDetails
Route of eliminationNot Available
Half life

36 +/- 13 hours

ClearanceNot Available
Toxicity

Oral, mouse LD50: 1737 mg/kg. Symptoms of overdose include nausea and vomiting, and withdrawal bleeding may occur in females. The FDA label includes a black box warning that states that combination oral contraceptives with ethinyl estradiol should not be used in women over 35 years old who smoke due to the increased risk of serious cardiovascular side effects.

Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with 1,10-Phenanthroline.Experimental
16-BromoepiandrosteroneThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Ethinyl Estradiol.Investigational
19-norandrostenedioneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Ethinyl Estradiol.Experimental, Illicit
2,4-thiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Ethinyl Estradiol.Investigational
3,4-DichloroisocoumarinThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with 3,4-Dichloroisocoumarin.Experimental
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.Experimental
5-androstenedioneThe serum concentration of 5-androstenedione can be increased when it is combined with Ethinyl Estradiol.Experimental, Illicit
AbciximabEthinyl Estradiol may decrease the anticoagulant activities of Abciximab.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational
AcenocoumarolEthinyl Estradiol may decrease the anticoagulant activities of Acenocoumarol.Approved
AcetaminophenThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Acetaminophen.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Ethinyl Estradiol.Withdrawn
AcitretinThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Acitretin.Approved
AdapaleneThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Adapalene.Approved
AfatinibThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Afatinib.Approved
AICA ribonucleotideThe therapeutic efficacy of Aicar can be decreased when used in combination with Ethinyl Estradiol.Experimental
AlbendazoleThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Albendazole.Approved, Vet Approved
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Ethinyl Estradiol.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Ethinyl Estradiol.Experimental
AlectinibThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Alfentanil.Approved, Illicit
AlitretinoinThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Alitretinoin.Approved, Investigational
AlogliptinThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Alpha-1-proteinase inhibitor.Approved
AmantadineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Amantadine.Approved
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be increased when it is combined with Ethinyl Estradiol.Experimental
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Ethinyl Estradiol.Approved
Aminohippuric acidThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Aminohippuric acid.Approved
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Ethinyl Estradiol.Approved
AmiodaroneThe metabolism of Ethinyl Estradiol can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Amlodipine.Approved
AmobarbitalThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Amobarbital.Approved, Illicit
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Ethinyl Estradiol.Approved
AmprenavirThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Amsacrine.Approved
AnastrozoleThe therapeutic efficacy of Anastrozole can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational
AncrodEthinyl Estradiol may decrease the anticoagulant activities of Ancrod.Investigational
AndrostenedioneThe serum concentration of 4-Androstenedione can be increased when it is combined with Ethinyl Estradiol.Experimental, Illicit
AnecortaveThe serum concentration of Anecortave can be increased when it is combined with Ethinyl Estradiol.Investigational
Anthrax immune globulin humanEthinyl Estradiol may increase the thrombogenic activities of Anthrax immune globulin human.Approved
Antithrombin III humanThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Apixaban.Approved
AprepitantThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Aprotinin.Approved, Withdrawn
ArdeparinEthinyl Estradiol may decrease the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Argatroban.Approved, Investigational
ArmodafinilThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Armodafinil.Approved, Investigational
ArtemetherThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Artemether.Approved
AstemizoleThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe metabolism of Ethinyl Estradiol can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Atenolol.Approved
AtomoxetineThe metabolism of Ethinyl Estradiol can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Atorvastatin.Approved
AzelastineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Azithromycin.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Ethinyl Estradiol.Investigational
BarbexacloneThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Barbexaclone.Experimental
BarbitalThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Barbital.Illicit
BatimastatThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Batimastat.Experimental
BecaplerminEthinyl Estradiol may decrease the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Ethinyl Estradiol.Approved, Investigational
BenazeprilThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Benazepril.Approved, Investigational
BenzamidineThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Benzamidine.Experimental
BenzocaineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Ethinyl Estradiol.Approved, Vet Approved
BexaroteneThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Biperiden.Approved
BivalirudinThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Boceprevir.Withdrawn
BortezomibThe metabolism of Ethinyl Estradiol can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Bosutinib.Approved
BromocriptineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Bromocriptine.Approved, Investigational
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Ethinyl Estradiol.Approved
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Ethinyl Estradiol.Withdrawn
BuprenorphineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Cabazitaxel.Approved
CaffeineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Caffeine.Approved
CanagliflozinThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Candesartan.Approved
CandoxatrilThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Candoxatrilat.Experimental
CaptoprilThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Captopril.Approved
CarbamazepineThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Carbamazepine.Approved, Investigational
CarvedilolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Caspofungin.Approved
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Ethinyl Estradiol.Experimental
CelecoxibCelecoxib may increase the thrombogenic activities of Ethinyl Estradiol.Approved, Investigational
CeritinibThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Ceritinib.Approved
CertoparinEthinyl Estradiol may decrease the anticoagulant activities of Certoparin.Approved
Chenodeoxycholic acidThe therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Ethinyl Estradiol.Approved
ChloroquineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorpromazineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholesterolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Cholesterol.Experimental
CholestyramineThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Cholestyramine.Approved
Cholic AcidEthinyl Estradiol may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Approved
ChymostatinThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Chymostatin.Experimental
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Ethinyl Estradiol.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Ethinyl Estradiol.Experimental
CilastatinThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Citalopram.Approved
Citric AcidEthinyl Estradiol may decrease the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClarithromycinThe metabolism of Ethinyl Estradiol can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Ethinyl Estradiol can be decreased when combined with Clemastine.Approved
ClobazamThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Clobazam.Approved, Illicit
ClobetasolThe serum concentration of Clobetasol can be increased when it is combined with Ethinyl Estradiol.Investigational
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Ethinyl Estradiol.Approved
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Ethinyl Estradiol.Approved
ClofazimineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClotrimazoleThe metabolism of Ethinyl Estradiol can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Cobicistat.Approved
ColchicineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Colchicine.Approved
ColesevelamThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Colesevelam.Approved
ColestipolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Colestipol.Approved
ColforsinThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Colforsin.Experimental
Conestat alfaEthinyl Estradiol may increase the thrombogenic activities of C1 Esterase Inhibitor (Recombinant).Approved
ConivaptanThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Conivaptan.Approved, Investigational
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Ethinyl Estradiol.Approved
CrizotinibThe metabolism of Ethinyl Estradiol can be decreased when combined with Crizotinib.Approved
CyclophosphamideThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe metabolism of Ethinyl Estradiol can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Dactinomycin.Approved
DalteparinEthinyl Estradiol may decrease the anticoagulant activities of Dalteparin.Approved
DanaparoidEthinyl Estradiol may decrease the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Ym150.Investigational
DarunavirThe metabolism of Ethinyl Estradiol can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Ethinyl Estradiol can be decreased when combined with Delavirdine.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Ethinyl Estradiol.Investigational
DesipramineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Desipramine.Approved
DesirudinEthinyl Estradiol may decrease the anticoagulant activities of Desirudin.Approved
DesloratadineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Desloratadine.Approved, Investigational
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Ethinyl Estradiol.Approved
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Ethinyl Estradiol.Approved
Desoxycorticosterone PivalateThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Ethinyl Estradiol.Experimental, Vet Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Ethinyl Estradiol.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Ethinyl Estradiol.Vet Approved
DextranEthinyl Estradiol may decrease the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Ethinyl Estradiol may decrease the anticoagulant activities of Dextran 40.Approved
Dextran 70Ethinyl Estradiol may decrease the anticoagulant activities of Dextran 70.Approved
Dextran 75Ethinyl Estradiol may decrease the anticoagulant activities of Dextran 75.Approved
DextromethorphanThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Dextromethorphan.Approved
DiclofenacThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Diclofenac.Approved, Vet Approved
DicoumarolEthinyl Estradiol may decrease the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Ethinyl Estradiol.Approved
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Ethinyl Estradiol.Approved
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Ethinyl Estradiol.Approved
DigoxinThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Digoxin.Approved
DihydroergotamineThe metabolism of Ethinyl Estradiol can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Ethinyl Estradiol can be decreased when combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Dipyridamole.Approved
DoxazosinThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Ethinyl Estradiol can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Ethinyl Estradiol can be decreased when combined with Dronedarone.Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Ethinyl Estradiol.Approved
DyphyllineThe serum concentration of Dyphylline can be increased when it is combined with Ethinyl Estradiol.Approved
EcabetThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Ecabet.Approved, Investigational
Edetic AcidEthinyl Estradiol may decrease the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Edoxaban.Approved
EfavirenzThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Efavirenz.Approved, Investigational
ElafinThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Elafin.Investigational
ElbasvirThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Elbasvir.Approved
ElvitegravirThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Elvitegravir.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ethinyl Estradiol.Approved
EnalaprilThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Enalkiren.Experimental
EnoxaparinEthinyl Estradiol may decrease the anticoagulant activities of Enoxaparin.Approved
EnzalutamideThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Enzalutamide.Approved
EquileninThe serum concentration of Equilenin can be increased when it is combined with Ethinyl Estradiol.Experimental
EquilinThe serum concentration of Equilin can be increased when it is combined with Ethinyl Estradiol.Approved
ErgonovineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Ergotamine.Approved
ErythromycinThe metabolism of Ethinyl Estradiol can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstramustineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Ethinyl Estradiol.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be increased when it is combined with Ethinyl Estradiol.Approved
Ethyl biscoumacetateEthinyl Estradiol may decrease the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the thrombogenic activities of Ethinyl Estradiol.Approved, Investigational, Vet Approved
EtoposideThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Etoposide.Approved
EtoricoxibEtoricoxib may increase the thrombogenic activities of Ethinyl Estradiol.Approved, Investigational
EtravirineThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Etravirine.Approved
ExemestaneThe therapeutic efficacy of Exemestane can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational
ExenatideThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Exenatide.Approved, Investigational
FaldaprevirThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Bi201335.Investigational
FelbamateThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Felbamate.Approved
FelodipineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Fidaxomicin.Approved
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Ethinyl Estradiol.Approved
fluasteroneThe serum concentration of fluasterone can be increased when it is combined with Ethinyl Estradiol.Investigational
FluconazoleThe metabolism of Ethinyl Estradiol can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Ethinyl Estradiol.Approved
FluindioneEthinyl Estradiol may decrease the anticoagulant activities of Fluindione.Investigational
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Ethinyl Estradiol.Approved, Vet Approved
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Ethinyl Estradiol.Approved, Investigational
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Ethinyl Estradiol.Approved, Investigational, Vet Approved
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Ethinyl Estradiol.Approved, Investigational
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Ethinyl Estradiol.Approved, Withdrawn
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Ethinyl Estradiol.Approved
FluoxetineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Fluphenazine.Approved
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Ethinyl Estradiol.Approved, Withdrawn
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Ethinyl Estradiol.Approved
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Ethinyl Estradiol.Approved
FlurazepamThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Flurazepam.Approved, Illicit
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Ethinyl Estradiol.Approved
Fluticasone propionateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Ethinyl Estradiol.Approved
FluvoxamineThe metabolism of Ethinyl Estradiol can be decreased when combined with Fluvoxamine.Approved, Investigational
FondaparinuxEthinyl Estradiol may decrease the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumEthinyl Estradiol may decrease the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FormestaneThe serum concentration of Formestane can be increased when it is combined with Ethinyl Estradiol.Approved, Investigational, Withdrawn
FosamprenavirThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Fosinopril.Approved
FosphenytoinThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Fusidic Acid.Approved
GabexateThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Gabexate.Investigational
GefitinibThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Gefitinib.Approved, Investigational
GeldanamycinThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Geldanamycin.Experimental
GenisteinThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Genistein.Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Ethinyl Estradiol.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Ethinyl Estradiol.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Ethinyl Estradiol.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Ethinyl Estradiol.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Ethinyl Estradiol.Approved
GlyburideThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Glyburide.Approved
GM6001The serum concentration of Ethinyl Estradiol can be decreased when it is combined with GM6001.Experimental
Gramicidin DThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Grepafloxacin.Withdrawn
GriseofulvinThe metabolism of Ethinyl Estradiol can be increased when combined with Griseofulvin.Approved, Vet Approved
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Ethinyl Estradiol.Investigational
HaloperidolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Haloperidol.Approved
HE3286The serum concentration of HE3286 can be increased when it is combined with Ethinyl Estradiol.Investigational
HeparinEthinyl Estradiol may decrease the anticoagulant activities of Heparin.Approved, Investigational
HexobarbitalThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Hexobarbital.Approved
Human C1-esterase inhibitorEthinyl Estradiol may increase the thrombogenic activities of C1 Esterase Inhibitor (Human).Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Ethinyl Estradiol.Approved, Vet Approved
IdelalisibThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Idelalisib.Approved
IdraparinuxThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with idraparinux.Investigational
ImatinibThe metabolism of Ethinyl Estradiol can be decreased when combined with Imatinib.Approved
ImidaprilThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Imidapril.Investigational
ImipramineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Imipramine.Approved
IndinavirThe metabolism of Ethinyl Estradiol can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Indomethacin.Approved, Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Ethinyl Estradiol.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Ethinyl Estradiol.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Ethinyl Estradiol.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Ethinyl Estradiol.Approved
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Ethinyl Estradiol.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Ethinyl Estradiol.Approved
IsavuconazoniumThe metabolism of Ethinyl Estradiol can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Isoflurophate.Approved, Withdrawn
IsotretinoinThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Isotretinoin.Approved
IsradipineThe metabolism of Ethinyl Estradiol can be decreased when combined with Isradipine.Approved
IstaroximeThe serum concentration of Istaroxime can be increased when it is combined with Ethinyl Estradiol.Investigational
ItraconazoleThe metabolism of Ethinyl Estradiol can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Ivermectin.Approved, Vet Approved
IxazomibThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Ixazomib.Approved
KetamineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleThe metabolism of Ethinyl Estradiol can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Ethinyl Estradiol.Approved, Investigational
LansoprazoleThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Lapatinib.Approved, Investigational
LenalidomideEthinyl Estradiol may increase the thrombogenic activities of Lenalidomide.Approved
LepirudinThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Lepirudin.Approved
LevofloxacinThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Levofloxacin.Approved, Investigational
LevothyroxineThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Linagliptin.Approved
LiothyronineThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Liotrix.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Ethinyl Estradiol.Approved
LisinoprilThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Lisinopril.Approved, Investigational
LomitapideThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Loperamide.Approved
LopinavirThe metabolism of Ethinyl Estradiol can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Loratadine.Approved
LosartanThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Losartan.Approved
LovastatinThe metabolism of Ethinyl Estradiol can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibLumiracoxib may increase the thrombogenic activities of Ethinyl Estradiol.Approved, Investigational
MaprotilineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Maprotiline.Approved
ME-609The serum concentration of ME-609 can be increased when it is combined with Ethinyl Estradiol.Investigational
MebendazoleThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Mebendazole.Approved, Vet Approved
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Ethinyl Estradiol.Approved
MefloquineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Ethinyl Estradiol.Vet Approved
MeprobamateThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Meprobamate.Approved, Illicit
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Ethinyl Estradiol.Approved
MethadoneThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Methadone.Approved
MethohexitalThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Methohexital.Approved
MethylphenobarbitalThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Ethinyl Estradiol.Approved, Vet Approved
MetoprololThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Metoprolol.Approved, Investigational
MetreleptinThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Metreleptin.Approved
MibefradilThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Ethinyl Estradiol.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Ethinyl Estradiol.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational
MitomycinThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Mitoxantrone.Approved, Investigational
ModafinilThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Moexipril.Approved
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Ethinyl Estradiol.Approved, Vet Approved
MorphineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Morphine.Approved, Investigational
Mycophenolic acidThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Mycophenolic acid.Approved
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NabumetoneNabumetone may increase the thrombogenic activities of Ethinyl Estradiol.Approved
NadroparinEthinyl Estradiol may decrease the anticoagulant activities of Nadroparin.Approved
NafamostatThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Nafamostat.Approved, Investigational
NafcillinThe metabolism of Ethinyl Estradiol can be increased when combined with Nafcillin.Approved
NaltrexoneThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Naringenin.Experimental
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational
NCX 1022The serum concentration of NCX 1022 can be increased when it is combined with Ethinyl Estradiol.Investigational
NefazodoneThe metabolism of Ethinyl Estradiol can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Ethinyl Estradiol can be decreased when combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Nifedipine.Approved
NilotinibThe metabolism of Ethinyl Estradiol can be decreased when combined with Nilotinib.Approved, Investigational
NisoldipineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Nitrendipine.Approved
NitroaspirinThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Nitroaspirin.Investigational
NorethisteroneThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Norethisterone.Approved
OlaparibThe metabolism of Ethinyl Estradiol can be decreased when combined with Olaparib.Approved
Oleoyl-estroneThe serum concentration of Oleoyl estrone can be increased when it is combined with Ethinyl Estradiol.Investigational
OmapatrilatThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Omapatrilat.Investigational
OmeprazoleThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Osimertinib.Approved
OspemifeneThe risk or severity of adverse effects can be increased when Ethinyl Estradiol is combined with Ospemifene.Approved
OtamixabanThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Otamixaban.Investigational
OxcarbazepineThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Oxcarbazepine.Approved
P-NitrophenolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Palmitic Acid.Experimental
PantoprazoleThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Pantoprazole.Approved
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Ethinyl Estradiol.Approved
ParecoxibParecoxib may increase the thrombogenic activities of Ethinyl Estradiol.Approved
ParoxetineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Paroxetine.Approved, Investigational
PentobarbitalThe metabolism of Ethinyl Estradiol can be increased when combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateEthinyl Estradiol may decrease the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Perindopril.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Ethinyl Estradiol.Approved, Withdrawn
PhenindioneEthinyl Estradiol may decrease the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Ethinyl Estradiol can be increased when combined with Phenobarbital.Approved
PhenprocoumonEthinyl Estradiol may decrease the anticoagulant activities of Phenprocoumon.Approved
PhenytoinThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Phosphoramidon.Experimental
PimozideThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Pimozide.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational
Platelet Activating FactorThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Platelet Activating Factor.Experimental
PonatinibThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe metabolism of Ethinyl Estradiol can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Ethinyl Estradiol.Approved, Nutraceutical
Prasterone sulfateThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Ethinyl Estradiol.Investigational
PravastatinThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Prazosin.Approved
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Ethinyl Estradiol.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Ethinyl Estradiol.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Ethinyl Estradiol.Approved, Vet Approved
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Ethinyl Estradiol.Experimental
PrimidoneThe metabolism of Ethinyl Estradiol can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Prinomastat.Investigational
ProbenecidThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Propranolol.Approved, Investigational
Protein CEthinyl Estradiol may decrease the anticoagulant activities of Protein C.Approved
Protein S humanEthinyl Estradiol may decrease the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeEthinyl Estradiol may decrease the anticoagulant activities of Protocatechualdehyde.Approved
ProtriptylineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Prucalopride.Approved
QuercetinThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Quercetin.Experimental
QuinacrineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Quinacrine.Approved
QuinaprilThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Quinine.Approved
RacecadotrilThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Racecadotril.Investigational
RamiprilThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Ramipril.Approved
RanitidineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Regorafenib.Approved
RemikirenThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Remikiren.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational
ReserpineThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Reserpine.Approved
ReviparinEthinyl Estradiol may decrease the anticoagulant activities of Reviparin.Approved
RifabutinThe metabolism of Ethinyl Estradiol can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Ethinyl Estradiol can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Ethinyl Estradiol can be increased when combined with Rifapentine.Approved
RilpivirineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Rilpivirine.Approved
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Ethinyl Estradiol.Approved
RitonavirThe metabolism of Ethinyl Estradiol can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Rivaroxaban.Approved
RofecoxibRofecoxib may increase the thrombogenic activities of Ethinyl Estradiol.Investigational, Withdrawn
RolapitantThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Rolapitant.Approved
RopiniroleThe serum concentration of Ropinirole can be increased when it is combined with Ethinyl Estradiol.Approved, Investigational
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational
RufinamideThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Rufinamide.Approved
SaquinavirThe metabolism of Ethinyl Estradiol can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Saxagliptin.Approved
ScopolamineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Secobarbital.Approved, Vet Approved
SelegilineThe serum concentration of Selegiline can be increased when it is combined with Ethinyl Estradiol.Approved, Investigational, Vet Approved
SertralineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Sertraline.Approved
SildenafilThe metabolism of Ethinyl Estradiol can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Sitagliptin.Approved, Investigational
SomatotropinThe therapeutic efficacy of Somatropin recombinant can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational
SorafenibThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Sorafenib.Approved, Investigational
SpiraprilThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Spirapril.Approved
SpironolactoneThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Streptozocin.Approved
SulfinpyrazoneThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Ethinyl Estradiol can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulodexideEthinyl Estradiol may decrease the anticoagulant activities of Sulodexide.Approved, Investigational
SumatriptanThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Taurocholic Acid.Experimental
TelaprevirThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Telaprevir.Withdrawn
TelithromycinThe metabolism of Ethinyl Estradiol can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Telmisartan.Approved, Investigational
TemocaprilThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Temsirolimus.Approved
TerazosinThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Terfenadine.Withdrawn
TesmilifeneThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Testosterone.Approved, Investigational
ThalidomideEthinyl Estradiol may increase the thrombogenic activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Ethinyl Estradiol.Approved
ThiamylalThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Thiamylal.Approved, Vet Approved
ThiopentalThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Thiopental.Approved, Vet Approved
ThiorphanThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Thiorphan.Experimental
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Ethinyl Estradiol.Approved
TicagrelorThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Ethinyl Estradiol can be decreased when combined with Ticlopidine.Approved
TipranavirEthinyl Estradiol may increase the dermatologic adverse activities of Tipranavir.Approved, Investigational
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Ethinyl Estradiol.Approved
TocilizumabThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Tocilizumab.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Ethinyl Estradiol.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Ethinyl Estradiol.Approved
TolvaptanThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Tolvaptan.Approved
TopiramateThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Topiramate.Approved
TrandolaprilThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Trandolapril.Approved
Tranexamic AcidEthinyl Estradiol may increase the thrombogenic activities of Tranexamic Acid.Approved
TrazodoneThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Trazodone.Approved, Investigational
TretinoinThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Tretinoin.Approved, Investigational, Nutraceutical
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Ethinyl Estradiol.Approved, Vet Approved
TrifluoperazineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Trimipramine.Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Ethinyl Estradiol.Withdrawn
UbenimexThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Ubenimex.Experimental
UlinastatinThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Ulinastatin.Investigational
Ursodeoxycholic acidThe therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational
ValdecoxibValdecoxib may increase the thrombogenic activities of Ethinyl Estradiol.Investigational, Withdrawn
VenlafaxineThe metabolism of Ethinyl Estradiol can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Ethinyl Estradiol can be decreased when combined with Verapamil.Approved
VildagliptinThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Vildagliptin.Approved, Investigational
VinblastineThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Vinorelbine.Approved, Investigational
Vitamin CThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Vitamin C.Approved, Nutraceutical
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Ethinyl Estradiol.Approved, Investigational
VoriconazoleThe metabolism of Ethinyl Estradiol can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinEthinyl Estradiol may decrease the anticoagulant activities of Warfarin.Approved
XimelagatranThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Ethinyl Estradiol can be decreased when combined with Ziprasidone.Approved
Food InteractionsNot Available
References
Synthesis Reference

Andreas Sachse, "Method of female hormonal contraception using a fixed extended cycle hormonal preparation containing dienogest and ethinyl estradiol." U.S. Patent US20060079491, issued April 13, 2006.

US20060079491
General ReferencesNot Available
External Links
ATC CodesG03AA03 — Lynestrenol and ethinylestradiolG03AA04 — Megestrol and ethinylestradiolG03AB07 — Chlormadinone and ethinylestradiolG03AA10 — Gestodene and ethinylestradiolG03AA08 — Medroxyprogesterone and ethinylestradiolG03AA11 — Norgestimate and ethinylestradiolG03AB01 — Megestrol and ethinylestradiolG03AB05 — Desogestrel and ethinylestradiolG03AA09 — Desogestrel and ethinylestradiolG03AB03 — Levonorgestrel and ethinylestradiolG03AB02 — Lynestrenol and ethinylestradiolL02AA03 — EthinylestradiolG03CA01 — EthinylestradiolG03AB04 — Norethisterone and ethinylestradiolG03AA16 — Dienogest and ethinylestradiolG03AA07 — Levonorgestrel and ethinylestradiolG03AA12 — Drospirenone and ethinylestradiolG03AB06 — Gestodene and ethinylestradiolG03AA02 — Quingestanol and ethinylestradiolG03AA06 — Norgestrel and ethinylestradiolG03AA05 — Norethisterone and ethinylestradiolG03AA13 — Norelgestromin and ethinylestradiolG03AA15 — Chlormadinone and ethinylestradiolG03AA01 — Etynodiol and ethinylestradiol
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (470 KB)
MSDSDownload (73.9 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingSupportive CareEndometriosis of Uterus1
1CompletedNot AvailableBioequivalence1
1CompletedNot AvailableChronic Hepatitis C Infection1
1CompletedNot AvailableHealthy Volunteers4
1CompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
1CompletedBasic ScienceFollicle Count / Follicle Size / Induction of follicle development / Oral Contraceptives (OC) / Ovarian Follicle1
1CompletedBasic ScienceHIV/AIDS1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedBasic ScienceHealthy Volunteers / Pharmacokinetics of Mirabegron1
1CompletedOtherHealthy Female Volunteers / Type 2 Diabetes Mellitus1
1CompletedOtherHealthy Volunteers1
1CompletedTreatmentContraception2
1CompletedTreatmentDiabetes / Type 2 Diabetes Mellitus1
1CompletedTreatmentHIV/AIDS / Human Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentHealthy Volunteers4
1CompletedTreatmentHepatitis C, Chronic1
1CompletedTreatmentMajor Depressive Disorder (MDD)1
1CompletedTreatmentType 2 Diabetes Mellitus2
1RecruitingHealth Services ResearchHIV Disease1
1RecruitingOtherHealthy Volunteers1
1RecruitingPreventionContraception1
1RecruitingTreatmentHealthy Volunteers1
1RecruitingTreatmentTumors, Solid1
1TerminatedNot AvailableCystic Fibrosis Exacerbations While on and Off Hormonal Contraception1
1TerminatedNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
1TerminatedTreatmentHealthy Volunteers1
1Unknown StatusTreatmentPolycystic Ovaries Syndrome1
1, 2Active Not RecruitingPreventionContraception / Hemostasis Parameter / Liver Metabolism1
2Active Not RecruitingTreatmentPolycystic Ovarian Syndrome1
2CompletedBasic ScienceHemostasis / Oral Contraceptives (OC)2
2CompletedPreventionBreakthrough Bleeding1
2CompletedPreventionContraception2
2CompletedPreventionEndometrial Cancers1
2CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections / Pregnancy1
2CompletedPreventionMigraines1
2CompletedTreatmentBone Mineral Density1
2CompletedTreatmentContraception1
2CompletedTreatmentContraception / Ovulation Inhibition1
2CompletedTreatmentDysmenorrhea1
2CompletedTreatmentOral Contraceptives (OC)1
2CompletedTreatmentOvulation1
2CompletedTreatmentOvulation Suppression1
2RecruitingPreventionPrevention of Pregnancy1
2RecruitingTreatmentAnorexia Nervosa (AN)1
2RecruitingTreatmentPolycystic Ovarian Syndrome1
2TerminatedTreatmentContraception / Ovulation Inhibition1
2TerminatedTreatmentDepressive State / PMDD / Premenstrual Dysphoric Disorder / Premenstrual Syndrome1
2TerminatedTreatmentHidradenitis Suppurativa (HS)1
2Unknown StatusTreatmentContraception1
2, 3CompletedTreatmentFailed Induction of Labor1
3Active Not RecruitingTreatmentContraception1
3CompletedEducational/Counseling/TrainingOral Contraceptives (OC)1
3CompletedPreventionContraception13
3CompletedPreventionContraception / Neural Tube Defects (NTDs) / Oral Contraceptives (OC)1
3CompletedPreventionContraception / Oral Contraceptives (OC) / Ovulation Inhibition1
3CompletedTreatmentAcne Vulgaris4
3CompletedTreatmentContraception1
3CompletedTreatmentDysmenorrhea1
3CompletedTreatmentHealthy Volunteers4
3CompletedTreatmentOral Contraceptives (OC)1
3CompletedTreatmentPolycystic Ovaries Syndrome2
3CompletedTreatmentPremenstrual Dysphoric Disorder ( PMDD)1
3CompletedTreatmentPremenstrual Syndrome1
3CompletedTreatmentPrimary Dysmenorrhoea1
3CompletedTreatmentSystemic Lupus Erythematosus (SLE)1
3CompletedTreatmentTurner's Syndrome1
3RecruitingTreatmentBladder Cancers / Transitional Cell Carcinoma / Ureteral Cancer1
3RecruitingTreatmentCancer, Breast1
3RecruitingTreatmentExercise-related Amenorrhea1
3RecruitingTreatmentPrimary Ovarian Insufficiency1
3TerminatedPreventionContraception1
3Unknown StatusNot AvailableContraceptive Affecting Blood Pressure / Contraceptive Affecting the Autonomic Nervous System1
3Unknown StatusTreatmentOral Contraceptives (OC)1
3WithdrawnNot AvailableMetrorrhagia1
3WithdrawnTreatmentOsteopenia1
4Active Not RecruitingBasic ScienceCardiovascular Risks / Insulin Sensitivity / Perimenopausal Disorder1
4Active Not RecruitingPreventionBMI >30 kg/m2 / Cardiovascular Disease (CVD) / Insulin Resistance / Metabolic Syndromes1
4Active Not RecruitingTreatmentPolycystic Ovaries Syndrome1
4CompletedBasic ScienceAdverse Effect of Oral Contraceptives, Subsequent Encounter1
4CompletedBasic ScienceContraception1
4CompletedDiagnosticBody Weights / Contraceptive Usage1
4CompletedPreventionContraception1
4CompletedTreatmentContraception1
4CompletedTreatmentContraception / Menopause / Quality of Life1
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentInfertilities2
4CompletedTreatmentPolycystic Ovaries Syndrome1
4CompletedTreatmentPost coital contraception1
4CompletedTreatmentPremature Ovarian Failure (POF)1
4CompletedTreatmentPremenstrual Dysphoric Disorder1
4CompletedTreatmentPremenstrual Syndrome1
4CompletedTreatmentPrimary Dysmenorrhoea1
4Enrolling by InvitationTreatmentBody Weight Changes1
4Not Yet RecruitingPreventionHealthy, Reproductive Age Women / Post coital contraception1
4RecruitingBasic ScienceBone; Disorder, Development and Growth1
4RecruitingBasic ScienceContraception1
4RecruitingBasic ScienceOther Disorders of Bone Development and Growth1
4RecruitingPreventionBacterial Vaginosis (BV)1
4RecruitingPreventionBacterial Vaginosis (BV) / HIV Disease1
4RecruitingTreatmentContraception1
4RecruitingTreatmentContraception / HIV Disease1
4RecruitingTreatmentDysmenorrhea / Endometriosis / Interstitial Cystitis / Migraine Disorders / Pain, Chronic / Pelvic Pain / Visceral Pain1
4TerminatedNot AvailableInfertilities1
4TerminatedTreatmentAbnormal Uterine Bleeding, Unspecified / Uterine Bleeding Heavy1
4Unknown StatusNot AvailableDysmenorrhea / Endometriotic Cysts / Painful Intercourse / Pelvic Pain1
4Unknown StatusPreventionHyperandrogenism / Menstrual Irregularities / Polycystic Ovarian Syndrome1
4Unknown StatusTreatmentBacterial Vaginosis (BV)1
4Unknown StatusTreatmentContraceptive Methods Comparison1
4Unknown StatusTreatmentMenstrual Problem1
4WithdrawnTreatmentInfertilities1
Not AvailableActive Not RecruitingNot AvailableContraception / HIV Disease / Immune Cells (Mucosal and Systemic)1
Not AvailableActive Not RecruitingNot AvailableDysmenorrhea1
Not AvailableActive Not RecruitingTreatmentEndometriosis / Infertilities1
Not AvailableCompletedNot AvailableAcne Vulgaris2
Not AvailableCompletedNot AvailableAcne / Contraception / Premenstrual Syndrome1
Not AvailableCompletedNot AvailableContraception4
Not AvailableCompletedNot AvailableContraceptive Usage / Vaginal Epithelial Disruption1
Not AvailableCompletedNot AvailableHormonal Contraception1
Not AvailableCompletedNot AvailableMetabolic Syndromes / Polycystic Ovaries Syndrome1
Not AvailableCompletedNot AvailablePharmacokinetics1
Not AvailableCompletedBasic ScienceCoronary Heart Disease (CHD)1
Not AvailableCompletedHealth Services ResearchOvarian Follicle1
Not AvailableCompletedTreatmentContraception1
Not AvailableCompletedTreatmentContraception: Optional Applicator for Insertion of Vaginal Ring1
Not AvailableCompletedTreatmentDepressive State / Premenstrual Syndrome1
Not AvailableCompletedTreatmentHealthy Volunteers1
Not AvailableCompletedTreatmentHypermenorrhea1
Not AvailableCompletedTreatmentInsulin Resistance / Polycystic Ovaries Syndrome1
Not AvailableCompletedTreatmentSystemic Lupus Erythematosus (SLE)1
Not AvailableCompletedTreatmentTemporomandibular Joint Disorders1
Not AvailableCompletedTreatmentThrombosis, Venous1
Not AvailableNot Yet RecruitingTreatmentPremature Menopause / Primary Ovarian Insufficiency1
Not AvailableRecruitingNot AvailableInfertilities1
Not AvailableRecruitingBasic ScienceCystic Fibrosis (CF)1
Not AvailableRecruitingTreatmentHyperandrogenism / Metabolic Cardiovascular Syndrome1
Not AvailableTerminatedBasic ScienceContraception1
Not AvailableTerminatedPreventionAdolescents Seeking Contraception / Contraception Desired1
Not AvailableTerminatedTreatmentIn-Vitro Fertilization / Infertilities1
Not AvailableUnknown StatusBasic ScienceOral Contraceptives (OC)1
Not AvailableUnknown StatusTreatmentEndothelial Dysfunction / Polycystic Ovaries Syndrome1
Not AvailableUnknown StatusTreatmentFemale Contraception1
Not AvailableWithdrawnTreatmentDysmenorrhea / Menstruation Disorders / Menstruation Disturbances1
Pharmacoeconomics
Manufacturers
  • Schering corp sub schering plough corp
  • Pharmacia and upjohn co
  • Organon usa inc
Packagers
Dosage forms
FormRouteStrength
Kit
TabletOral.05 mg
TabletOral.5 mg
TabletOral.02 mg
Patch, extended releaseTransdermal
Tablet, film coatedOral
Tablet, chewableOral
Kit
KitOral
TabletOral
Insert, extended releaseVaginal
RingVaginal
PatchTransdermal
Prices
Unit descriptionCostUnit
Ethinyl estradiol powder140.0USD g
Ortho-Cyclen (28) 28 0.25-35 mg-mcg tablet Disp Pack38.99USD disp
Ortho tri-cyclen lo tablet2.68USD tablet
Ortho-cyclen 28 tablet1.13USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6156742 No2000-12-052020-12-05Us
US6787531 No2000-08-312020-08-31Us
US6933395 No1997-08-112017-08-11Us
US5876746 No1995-11-202015-11-20Us
US5989581 No1998-04-082018-04-08Us
US6214815 Yes1999-12-092019-12-09Us
US6667050 No1999-04-062019-04-06Us
US5898032 No1997-06-232017-06-23Us
USRE39861 No1997-06-232017-06-23Us
US6987101 No1997-12-222017-12-22Us
US7163931 No2001-12-202021-12-20Us
US6958326 No2001-12-202021-12-20Us
US5798338 No1995-07-102015-07-10Us
US7320969 No2004-01-302024-01-30Us
US7615545 No2003-06-152023-06-15Us
US7855190 No2008-12-052028-12-05Us
US7858605 No2003-06-232023-06-23Us
US6500814 No1998-09-032018-09-03Us
US7704984 No2009-02-022029-02-02Us
US6441168 No2002-07-302022-07-30Us
US8617597 No2010-02-082030-02-08Us
US8450299 No2005-10-072025-10-07Us
US8415332 No2009-03-112029-03-11Us
US6652880 No2000-03-292020-03-29Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point (°C)142-144Inhoffen, H.H. and Hohlweg, W.; U.S. Patent 2,265,976; December 9, 1941; assigned to Schering Corp.
water solubility11.3 mg/L (at 27 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP3.67HANSCH,C ET AL. (1995)
logS-4.3ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.00677 mg/mLALOGPS
logP3.63ALOGPS
logP3.9ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)10.33ChemAxon
pKa (Strongest Basic)-1.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area40.46 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity87.37 m3·mol-1ChemAxon
Polarizability34.53 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9965
Blood Brain Barrier+0.8546
Caco-2 permeable+0.8638
P-glycoprotein substrateSubstrate0.6892
P-glycoprotein inhibitor INon-inhibitor0.9006
P-glycoprotein inhibitor IINon-inhibitor0.9449
Renal organic cation transporterNon-inhibitor0.84
CYP450 2C9 substrateNon-substrate0.7178
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.715
CYP450 1A2 substrateInhibitor0.8941
CYP450 2C9 inhibitorNon-inhibitor0.9186
CYP450 2D6 inhibitorNon-inhibitor0.9506
CYP450 2C19 inhibitorNon-inhibitor0.6641
CYP450 3A4 inhibitorInhibitor0.5224
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6776
Ames testNon AMES toxic0.9155
CarcinogenicityNon-carcinogens0.8519
BiodegradationNot ready biodegradable0.9879
Rat acute toxicity2.4584 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8805
hERG inhibition (predictor II)Inhibitor0.5788
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Download (9.42 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted GC-MSPredicted GC-MS Spectrum - GC-MSNot Available
GC-MSGC-MS Spectrum - EI-Bsplash10-03di-0890000000-5219bc8ac1212313c9c0View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)splash10-000b-0290000000-0ef72fb5e00440b9ff50View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)splash10-000i-0960000000-945d82a0ab94f246ac88View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)splash10-056s-2910000000-0d38daebb87a39304e91View in MoNA
LC-MS/MSLC-MS/MS Spectrum - EI-B (HITACHI M-80) , Positivesplash10-03di-0890000000-7a166e952207cf7bc1d3View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-03dj-2980000000-831c8190c59f98fc8623View in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as estrogens and derivatives. These are steroids with a structure containing a 3-hydroxylated estrane.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassEstrane steroids
Direct ParentEstrogens and derivatives
Alternative Parents3-hydroxysteroids / 17-hydroxysteroids / Phenanthrenes and derivatives / Tetralins / 1-hydroxy-2-unsubstituted benzenoids / Ynones / Tertiary alcohols / Cyclic alcohols and derivatives / Acetylides / Hydrocarbon derivatives
SubstituentsEstrogen-skeleton / 3-hydroxysteroid / Hydroxysteroid / 17-hydroxysteroid / Phenanthrene / Tetralin / 1-hydroxy-2-unsubstituted benzenoid / Benzenoid / Ynone / Cyclic alcohol
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptorsterminal acetylenic compound, 17-hydroxy steroid, 3-hydroxy steroid (CHEBI:4903 ) / C18 steroids (estrogens) and derivatives (C07534 ) / C18 steroids (estrogens) and derivatives (LMST02010036 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription fact...
Gene Name:
ESR1
Uniprot ID:
P03372
Uniprot Name:
Estrogen receptor
Molecular Weight:
66215.45 Da
References
  1. Micevych PE, Chaban V, Ogi J, Dewing P, Lu JK, Sinchak K: Estradiol stimulates progesterone synthesis in hypothalamic astrocyte cultures. Endocrinology. 2007 Feb;148(2):782-9. Epub 2006 Nov 9. [PubMed:17095591 ]
  2. Garcia-Segura LM, Sanz A, Mendez P: Cross-talk between IGF-I and estradiol in the brain: focus on neuroprotection. Neuroendocrinology. 2006;84(4):275-9. Epub 2006 Nov 23. [PubMed:17124377 ]
  3. Brama M, Gnessi L, Basciani S, Cerulli N, Politi L, Spera G, Mariani S, Cherubini S, Scotto d'Abusco A, Scandurra R, Migliaccio S: Cadmium induces mitogenic signaling in breast cancer cell by an ERalpha-dependent mechanism. Mol Cell Endocrinol. 2007 Jan 29;264(1-2):102-8. Epub 2006 Nov 27. [PubMed:17125913 ]
  4. Lehnes K, Winder AD, Alfonso C, Kasid N, Simoneaux M, Summe H, Morgan E, Iann MC, Duncan J, Eagan M, Tavaluc R, Evans CH Jr, Russell R, Wang A, Hu F, Stoica A: The effect of estradiol on in vivo tumorigenesis is modulated by the human epidermal growth factor receptor 2/phosphatidylinositol 3-kinase/Akt1 pathway. Endocrinology. 2007 Mar;148(3):1171-80. Epub 2006 Nov 30. [PubMed:17138652 ]
  5. Mukai H, Tsurugizawa T, Ogiue-Ikeda M, Murakami G, Hojo Y, Ishii H, Kimoto T, Kawato S: Local neurosteroid production in the hippocampus: influence on synaptic plasticity of memory. Neuroendocrinology. 2006;84(4):255-63. Epub 2006 Dec 1. [PubMed:17142999 ]
  6. Notch EG, Mayer GD: 17alpha-Ethinylestradiol hinders nucleotide excision repair in zebrafish liver cells. Aquat Toxicol. 2009 Dec 13;95(4):273-8. doi: 10.1016/j.aquatox.2009.01.001. Epub 2009 Jan 23. [PubMed:19237207 ]
  7. Bennink HJ: Reprint of Are all estrogens the same? Maturitas. 2008 Sep-Oct;61(1-2):195-201. [PubMed:19434891 ]
  8. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism and secretion of potentially harmful xenobiotics, drugs and endogenous compounds. Activated by the antibiotic rifampicin and various plant metabolites, such as hyperforin, guggulipid, colupulone, and is...
Gene Name:
NR1I2
Uniprot ID:
O75469
Uniprot Name:
Nuclear receptor subfamily 1 group I member 2
Molecular Weight:
49761.245 Da
References
  1. Xue Y, Moore LB, Orans J, Peng L, Bencharit S, Kliewer SA, Redinbo MR: Crystal structure of the pregnane X receptor-estradiol complex provides insights into endobiotic recognition. Mol Endocrinol. 2007 May;21(5):1028-38. Epub 2007 Feb 27. [PubMed:17327420 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Androgen binding
Specific Function:
Functions as an androgen transport protein, but may also be involved in receptor mediated processes. Each dimer binds one molecule of steroid. Specific for 5-alpha-dihydrotestosterone, testosterone, and 17-beta-estradiol. Regulates the plasma metabolic clearance rate of steroid hormones by controlling their plasma concentration.
Gene Name:
SHBG
Uniprot ID:
P04278
Uniprot Name:
Sex hormone-binding globulin
Molecular Weight:
43778.755 Da
References
  1. Hong H, Branham WS, Ng HW, Moland CL, Dial SL, Fang H, Perkins R, Sheehan D, Tong W: Human sex hormone-binding globulin binding affinities of 125 structurally diverse chemicals and comparison with their binding to androgen receptor, estrogen receptor, and alpha-fetoprotein. Toxicol Sci. 2015 Feb;143(2):333-48. doi: 10.1093/toxsci/kfu231. Epub 2014 Oct 27. [PubMed:25349334 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Uniprot Name:
Cytochrome P450 3A4
Molecular Weight:
57342.67 Da
References
  1. Wang B, Sanchez RI, Franklin RB, Evans DC, Huskey SE: The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos. 2004 Nov;32(11):1209-12. Epub 2004 Aug 10. [PubMed:15304426 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Uniprot Name:
Cytochrome P450 2C8
Molecular Weight:
55824.275 Da
References
  1. Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. [PubMed:15601807 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Transporter activity
Specific Function:
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name:
ABCB11
Uniprot ID:
O95342
Uniprot Name:
Bile salt export pump
Molecular Weight:
146405.83 Da
References
  1. Lee JM, Trauner M, Soroka CJ, Stieger B, Meier PJ, Boyer JL: Expression of the bile salt export pump is maintained after chronic cholestasis in the rat. Gastroenterology. 2000 Jan;118(1):163-72. [PubMed:10611165 ]
  2. Huang L, Smit JW, Meijer DK, Vore M: Mrp2 is essential for estradiol-17beta(beta-D-glucuronide)-induced cholestasis in rats. Hepatology. 2000 Jul;32(1):66-72. [PubMed:10869290 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Virus receptor activity
Specific Function:
The hepatic sodium/bile acid uptake system exhibits broad substrate specificity and transports various non-bile acid organic compounds as well. It is strictly dependent on the extracellular presence of sodium.(Microbial infection) Acts as a receptor for hepatitis B virus.
Gene Name:
SLC10A1
Uniprot ID:
Q14973
Uniprot Name:
Sodium/bile acid cotransporter
Molecular Weight:
38118.64 Da
References
  1. Lee JM, Trauner M, Soroka CJ, Stieger B, Meier PJ, Boyer JL: Expression of the bile salt export pump is maintained after chronic cholestasis in the rat. Gastroenterology. 2000 Jan;118(1):163-72. [PubMed:10611165 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Uniprot Name:
Canalicular multispecific organic anion transporter 1
Molecular Weight:
174205.64 Da
References
  1. Kauffmann HM, Schrenk D: Sequence analysis and functional characterization of the 5'-flanking region of the rat multidrug resistance protein 2 (mrp2) gene. Biochem Biophys Res Commun. 1998 Apr 17;245(2):325-31. [PubMed:9571149 ]
  2. Trauner M, Arrese M, Soroka CJ, Ananthanarayanan M, Koeppel TA, Schlosser SF, Suchy FJ, Keppler D, Boyer JL: The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. Gastroenterology. 1997 Jul;113(1):255-64. [PubMed:9207286 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Uniprot Name:
Multidrug resistance protein 1
Molecular Weight:
141477.255 Da
References
  1. Kim WY, Benet LZ: P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul;21(7):1284-93. [PubMed:15290871 ]
Drug created on June 13, 2005 07:24 / Updated on September 01, 2017 10:34